Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study
Abstract
BACKGROUND:
The effect of myocardial infarction (MI) on life expectancy is difficult to study because the prevalence of MI hinders direct comparison with the life expectancy of the general population. We sought to assess this in relation to age, sex, and left ventricular ejection fraction (LVEF) by comparing individuals with MI with matched comparators without previous MI.
METHODS:
We included patients with a first MI between 1991 and 2022 from the nationwide SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), each matched with up to 5 comparators on age, sex, and region of residence. Flexible parametric survival models were used to estimate excess mortality and mean loss of life expectancy (LOLE) depending on index year, age, sex, and LVEF, and adjusted for differences in characteristics.
RESULTS:
A total of 335 748 cases were matched to 1 625 396 comparators. A higher LOLE was observed in younger individuals, women, and those with reduced LVEF (<50%). In 2022, the unadjusted and adjusted mean LOLE spanned from 11.1 and 9.5 years in 50-year-old women with reduced LVEF to 5 and 3.7 months in 80-year-old men with preserved LVEF. Between 1992 and 2022, the adjusted mean LOLE decreased by 36% to 55%: from 4.4 to 2.0 years and from 3.3 to 1.9 years in 50-year-old women and men, respectively, and from 1.7 to 1.0 years and from 1.4 to 0.9 years in 80-year-old women and men, respectively.
CONCLUSIONS:
LOLE is higher in younger individuals, women, and those with reduced LVEF, but is attenuated when adjusting for comorbidities and risk factors. Advances in MI treatment during the past 30 years have almost halved LOLE, with no clear sign of leveling off to a plateau.
Get full access to this article
View all available purchase options and get full access to this article.
Supplemental Material
File (circ_circulationaha-2024-068739_supp1.pdf)
- Download
- 1.48 MB
REFERENCES
1.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9
2.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, et al. Heart disease and stroke statistics: 2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–e621. doi: 10.1161/CIR.0000000000001123
3.
Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, James S, Kellerth T, Lindahl B, Ravn-Fischer A, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38:3056–3065. doi: 10.1093/eurheartj/ehx515
4.
Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research. J Am Coll Cardiol. 1999;34:618–620. doi: 10.1016/s0735-1097(99)00250-8
5.
Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51–64. doi: 10.1002/sim.1597
6.
Andersson TM-L, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32:5286–5300. doi: 10.1002/sim.5943
7.
Wenzl FA, Kraler S, Ambler G, Weston C, Herzog SA, Räber L, Muller O, Camici GG, Roffi M, Rickli H, et al. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. Lancet. 2022;400:744–756. doi: 10.1016/s0140-6736(22)01483-0
8.
Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non–ST-elevation MI: a method for prognostication and therapeutic decision making. ACC Curr J Rev. 2001;10:17. doi: 10.1016/s1062-1458(00)00159-8
9.
Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, Bhatt DL, Steg PG, Läll K, Mägi R, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;43:1715–1727. doi: 10.1093/eurheartj/ehac056
10.
De Bacquer D, Ueda P, Reiner Z, De Sutter J, De Smedt D, Lovic D, Gotcheva N, Fras Z, Pogosova N, Mirrakhimov E, et al. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE risk model. Eur J Prev Cardiol. 2022;29:328–339. doi: 10.1093/eurjpc/zwaa128
11.
Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart. 2010;96:1617–1621. doi: 10.1136/hrt.2010.198804
12.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;18:800–804. doi: 10.1097/ede.0b013e3181577654
13.
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) statement. PLoS Med. 2015;12:e1001885. doi: 10.1371/journal.pmed.1001885
14.
Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–2197. doi: 10.1002/sim.1203
15.
Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. Stata Press; 2011.
16.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022.
17.
Liu X-R, Pawitan Y, Clements M. Parametric and penalized generalized survival models. Stat Methods Med Res. 2018;27:1531–1546. doi: 10.1177/0962280216664760
18.
Jakobsen LH, Andersson TM-L, Biccler JL, El-Galaly TC, Bøgsted M. Estimating the loss of lifetime function using flexible parametric relative survival models. BMC Med Res Methodol. 2019;19:23. doi: 10.1186/s12874-019-0661-8
19.
Dickman PW, Adami H-O. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103–117. doi: 10.1111/j.1365-2796.2006.01677.x
20.
Bucholz EM, Normand S-LT, Wang Y, Ma S, Lin H, Krumholz HM. Life expectancy and years of potential life lost after acute myocardial infarction by sex and race: a cohort-based study of Medicare beneficiaries. J Am Coll Cardiol. 2015;66:645–655. doi: 10.1016/j.jacc.2015.06.022
21.
Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life expectancy after myocardial infarction, according to hospital performance. N Engl J Med. 2016;375:1332–1342. doi: 10.1056/nejmoa1513223
22.
Bucholz EM, Butala NM, Normand S-LT, Wang Y, Krumholz HM. Association of guideline-based admission treatments and life expectancy after myocardial infarction in elderly Medicare beneficiaries. J Am Coll Cardiol. 2016;67:2378–2391. doi: 10.1016/j.jacc.2016.03.507
23.
Nelson CP, Lambert PC, Squire IB, Jones DR. Relative survival: what can cardiovascular disease learn from cancer? Eur Heart J. 2008;29:941–947. doi: 10.1093/eurheartj/ehn079
24.
Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, Alfredsson J, Lindahl B, Jernberg T. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J Am Heart Assoc. 2017;6:e007123. doi: 10.1161/JAHA.117.007123
25.
Dai H, Much AA, Maor E, Asher E, Younis A, Xu Y, Lu Y, Liu X, Shu J, Bragazzi NL. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2022;8:50–60. doi: 10.1093/ehjqcco/qcaa076
26.
Bucholz EM, Butala NM, Rathore SS, Dreyer RP, Lansky AJ, Krumholz HM. Sex differences in long-term mortality after myocardial infarction: a systematic review. Circulation. 2014;130:757–767. doi: 10.1161/circulationaha.114.009480
27.
Jakobsen LH, Andersson TM-L, Biccler JL, El-Galaly TC, Bøgsted M. Estimating the loss of lifetime function using flexible parametric relative survival models. BMC Med Res Methodol. 2019;19:23. doi: 10.1186/s12874-019-0661-8
28.
Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–1367. doi: 10.1093/eurheartj/ehaa575
29.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64:e139–e228. doi: 10.1016/j.jacc.2014.09.017
Information & Authors
Information
Published In
Copyright
© 2024 American Heart Association, Inc.
Versions
You are viewing the most recent version of this article.
History
Received: 12 January 2024
Accepted: 11 June 2024
Published online: 5 July 2024
Published in print: 10 September 2024
Keywords
Subjects
Authors
Disclosures
Dr Reitan reports participation in research funded by MSD and AstraZeneca. Dr Andell has participated in research funded by and has received lecture fees to the institution from AstraZeneca. Dr Alfredsson has received lecture or advisory board fees from Boehringer Ingelheim, AstraZeneca, Novartis, Bayer, and MSD. Dr Erlinge has received speaker or advisory board fees from AstraZeneca, Novo Nordisk, Sanofi, Bayer, and Amgen. Dr Hofmann reports lecture fees to the institution from AstraZeneca, Pfizer, and BMS. Dr Lindahl reports no conflict of interest. Dr Simonsson reports lecture fees to the institution from Amgen, Novo Nordisk, and AstraZeneca. Dr Dickman reports no conflict of interest. Dr Jernberg reports research grants from MSD and consulting fees in a research project to the institution from Amgen.
Sources of Funding
The study was financed by grants from the Swedish state under an agreement between the Swedish government and the county councils (the ALF agreement) and the Swedish Heart and Lung Foundation.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Advances in Technology and Technique in Percutaneous Coronary Intervention: A Clinical Review, Internal Medicine, (2024).https://doi.org/10.2169/internalmedicine.4505-24
- Quantifying Longevity After Myocardial Infarction: What Is Lost and What Is Gained, Circulation, 150, 11, (836-837), (2024)./doi/10.1161/CIRCULATIONAHA.124.070996
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.